Montelukast effect in patients with chronic obstructive pulmonary disease

The effect of montelukast on the serum levels of inflammatory factors in patients with chronic obstructive pulmonary disease (COPD) in intervention and control groups

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190423043361N1

Enrollment

Registered

2019-08-26

Start date

2017-11-22

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease. Other chronic obstructive pulmonary disease

Interventions

Intervention 1: Intervention group: In one cycle of treatment the patients receives 10 mg of montelukast, Poursina factory production, once a day for two months. Intervention 2: Control group: The sam

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: COPD patients aged 40 to 70 years Patients with stable conditions in the last trimester Patients who are at stages II-III-IV of the disease

Exclusion criteria

Exclusion criteria: History of hospitalization History of long-term Corticosteroid use Other inflammatory diseases such as cardiovascular, rheumatic, pulmonary, and liver disease

Design outcomes

Primary

Measure	Time frame
TNF-a level. Timepoint: 60 days. Method of measurement: ELISA Diagnostic Kits.;Level of IL-18. Timepoint: 60 days. Method of measurement: ELISA Diagnostic Kits.;Levels of CRP. Timepoint: 60 days. Method of measurement: semiquantitative C-reactive protein latex agglutination kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Azargoon

Khoram-Abad University of Medical Sciences

nazanin.kordalivand97@gmail.com+98 66 3312 0238

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026